Results 211 to 220 of about 26,025 (223)

Venetoclax

Reactions Weekly, 2018
openaire   +1 more source

Venetoclax, bendamustine, and rituximab in patients with relapsed or refractory NHL: a phase Ib dose-finding study

Annals of Oncology, 2018
Christopher R Flowers
exaly  

Effect of Low‐ and High‐Fat Meals on the Pharmacokinetics of Venetoclax, a Selective First‐in‐Class BCL‐2 Inhibitor

Journal of Clinical Pharmacology, 2016
Ahmed Hamed Salem, Silpa Nuthalapati, David Chien   +2 more
exaly  

Effect of Azithromycin on Venetoclax Pharmacokinetics in Healthy Volunteers: Implications for Dosing Venetoclax with P-gp Inhibitors

Advances in Therapy, 2018
Ahmed Hamed Salem
exaly  

Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokinetics

European Journal of Clinical Pharmacology, 2018
Kevin J Freise, Ahmed Hamed Salem
exaly  

Venetoclax enhances NK cell killing sensitivity of AML cells through the NKG2D/NKG2DL activation pathway

International Immunopharmacology, 2022
exaly  

Evaluation of Rifampin's Transporter Inhibitory and CYP3A Inductive Effects on the Pharmacokinetics of Venetoclax, a BCL‐2 Inhibitor: Results of a Single‐ and Multiple‐Dose Study

Journal of Clinical Pharmacology, 2016
David Chien, Ahmed Hamed Salem
exaly  

Venetoclax does not prolong the QT interval in patients with hematological malignancies: an exposure–response analysis

Cancer Chemotherapy and Pharmacology, 2016
Kevin J Freise, Ahmed Hamed Salem
exaly  

Clinical evaluation of P-glycoprotein inhibition by venetoclax: a drug interaction study with digoxin

Xenobiotica, 2018
Manoj S Chiney, Ahmed Hamed Salem
exaly  

Pharmacokinetics of Venetoclax, a Novel BCL‐2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non‐Hodgkin Lymphoma

Journal of Clinical Pharmacology, 2017
Ahmed Hamed Salem
exaly